The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Activated extracellular signal‐regulated kinase is an independent prognostic factor in clinically confined renal cell carcinoma
Open accessAbstract
BACKGROUND: Extracellular signal‐regulated kinase (ERK) promotes proliferation, metastasis, and poor survival in cancers of the breast, lung, and liver. Advanced localized renal cell carcinoma (RCC) is extraordinarily treatment resistant and has high recurrence rates despite surgery. Limited data exist regarding the prognostic significance of activated (phosphorylated) ERK in RCC. The authors hypothesized that activated ERK (pERK) promotes disease progression and metastasis in localized RCC and may be of value as a biomarker to predict disease recurrence. METHODS: The expression profile of pERK was examined by immunocytochemistry using a tissue microarray constructed from 174 drug treatment–naive patients who had undergone radical nephrectomy for localized RCC. Levels of tumor‐cell specific pERK were scored and correlated with clinicopathologic parameters of RCC and disease‐free survival. RESULTS: Immunostaining for pERK was present in 36% of all RCCs, with a predominance found in the clear cell histologic subtype. High expression was associated with increased tumor size, increased TNM stage, and vascular invasion. Patients with pERK‐positive tumors had a mean disease‐free survival of 4.19 years, compared with 6.38 years for patients with pERK‐negative tumors (P < .001). Cox regression models revealed pERK to be a significant independent predictor of disease‐free survival, with a hazards score of 2.9 (P < .001), a value similar to tumor grade (hazards ratio, 3.01; P < .001). CONCLUSIONS: Expression of pERK is an independent prognostic factor in RCC that is associated with advanced and aggressive pathologic features of renal tumors and predicts the onset of metastasis in patients with localized disease. Cancer 2009. © 2009 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“constitutive activation of the ERK pathway is itself an independent factor associated with poor prognosis in RCC”
From PPP1R18-mediated activation of Wnt/β-catenin and EMT is dependent on ERK signaling in clear cell renal cell carcinoma (2026) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
Roberts, P. J., & Der, C. J. (2007) · Oncogene · doi:10.1038/sj.onc.1210422 · Cited by 2,788
Prognostic significance of morphologic parameters in renal cell carcinoma
Fuhrman, S. A., Lasky, L. C., & Limas, C. (1982) · The American Journal of Surgical Pathology · doi:10.1097/00000478-198210000-00007 · Cited by 2,724
The Heidelberg classification of renal cell tumours
Kovács, G., Akhtar, M., Beckwith, B., Bugert, P., Cooper, C. S., Delahunt, B., Eble, J. N., Fleming, S., Ljungberg, B., Medeiros, L. J., et al. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<131::aid-path931>3.0.co;2-g · Cited by 1,353
Gupta, K., Miller, J. D., Li, J. Z., Russell, M. W., & Charbonneau, C. (2008) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2007.12.001 · Cited by 974
Role of MAP kinase in tumor progression and invasion
Reddy, K. B., Nabha, S. M., & Atanaskova, N. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023781114568 · Cited by 517
Targeted Therapy for Metastatic Renal Cell Carcinoma
Motzer, R. J., & Bukowski, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5415 · Cited by 454
Gollob, J., Wilhelm, S. A., CARTER, C., & Kelley, S. K. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.002 · Cited by 368
Ebisuya, M., Kondoh, K., & Nishida, E. (2005) · Journal of Cell Science · doi:10.1242/jcs.02505 · Cited by 331
Cited by
SPOP Promotes Tumorigenesis by Acting as a Key Regulatory Hub in Kidney Cancer
Li, G., Ci, W., Karmakar, S., Chen, K., Dhar, R., Fan, Z., Guo, Z., Zhang, J., Ke, Y., Wang, L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.007 · Cited by 185
The potential role of leptin in tumor invasion and metastasis
Ray, A., & Cleary, M. P. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.11.002 · Cited by 157
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
Horiguchi, A., Asano, T., Kuroda, K., Sato, A., Asakuma, J., Ito, K., Hayakawa, M., Sumitomo, M., & Asano, T. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605691 · Cited by 123
Maeda, Y., Kawano, Y., Wada, Y., Yatsuda, J., Motoshima, T., Murakami, Y., Kikuchi, K., Imamura, T., & Eto, M. (2015) · Oncology Reports · doi:10.3892/or.2015.3800 · Cited by 56
Campbell, L., Aljayyoussi, G., Gutteridge, R., Gumbleton, N., Griffiths, R., Gumbleton, S., Smith, M. W., Griffiths, D. F., & Gumbleton, M. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-255 · Cited by 36
Self-citationMakino, T., Izumi, K., Hiratsuka, K., Kano, H., Shimada, T., Nakano, T., Kadomoto, S., Naito, R., Iwamoto, H., Yaegashi, H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-80302-4 · Cited by 35
Chen, C., Hsieh, S.-C., Lin, C., Lin, Y.-S., Tsai, J., & Hsieh, Y. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000485582 · Cited by 35
Suzuki, K., Mizuno, R., Suenaga, K., Teruya, T., Tanaka, N., Kosaka, T., & Oya, M. (2013) · Cancer Medicine · doi:10.1002/cam4.53 · Cited by 30
Runx3 is a crucial regulator of alveolar differentiation and lung tumorigenesis in mice
Lee, J., Shin, J.-O., Cho, K., Hosoya, A., Cho, S. W., Lee, Y., Ryoo, H., Bae, S., & Jung, H.-S. (2011) · Differentiation · doi:10.1016/j.diff.2011.02.001 · Cited by 29
Takahashi, M., Tsukamoto, Y., Kai, T., Tokunaga, A., Nakada, C., Hijiya, N., Uchida, T., Daa, T., Nomura, T., Sato, F., et al. (2016) · Cancer Science · doi:10.1111/cas.12892 · Cited by 28
MicroRNA target site polymorphisms in the VHL‐HIF1α pathway predict renal cell carcinoma risk
Wei, H., Ke, H., Lin, J. M., Shete, S. S., Wood, C. G., & Hildebrandt, M. A. T. (2012) · Molecular Carcinogenesis · doi:10.1002/mc.21917 · Cited by 24
Ribeiro, A. L. R., Nobre, R. M., Júnior, S. D. M. A., Kataoka, M. S. S., Barroso, R. F. F., Jaeger, R. G., & Pinheiro, J. D. J. V. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2012.06.011 · Cited by 23
Activation of MEK1/2‐ERK1/2 signaling during NNK‐induced lung carcinogenesis in female A/J mice
Yamakawa, K., Yokohira, M., Nakano, Y., Kishi, S., Kanie, S., & Imaida, K. (2016) · Cancer Medicine · doi:10.1002/cam4.652 · Cited by 20
Sharma, U., Pal, D., & Prasad, R. (2014) · Biochimie · doi:10.1016/j.biochi.2014.09.016 · Cited by 20
Theocharis, S. E., Kotta‐Loizou, I., Klijanienko, J., Giaginis, C., Alexandrou, P. T., Danas, E., Rodriguez, J., Patsouris, E., & Sastre‐Garau, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-1853-9 · Cited by 19
Brown, R. E., Buryanek, J., Tammisetti, V. S., McGuire, M. F., & Smith, K. C. (2016) · Oncotarget · doi:10.18632/oncotarget.9508 · Cited by 15
Hu, W. M., Yuan, Q., Liu, X., Zhu, H., Sheng-qi, L., & Wang, X. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.12.025 · Cited by 13
Redox‐sensitive signaling pathways in renal cell carcinoma
Cruz‐Gregorio, A., Aranda‐Rivera, A. K., Pedraza‐Chaverrí, J., Solano, J. D., & Ibarra‐Rubio, M. E. (2021) · BioFactors · doi:10.1002/biof.1784 · Cited by 12
Initial analysis of peripheral lymphocytic extracellular signal related kinase activation in autism
Erickson, C. A., Ray, B., Wink, L. K., Bayon, B. L., Pedapati, E. V., Shaffer, R. C., Schaefer, T. L., & Lahiri, D. K. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.003 · Cited by 10
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus
Nakai, Y., Miyake, M., Morizawa, Y., Hori, S., Tatsumi, Y., Anai, S., Onishi, S., Tanaka, N., & Fujimoto, K. (2016) · Oncology Reports · doi:10.3892/or.2016.5232 · Cited by 9
Wu, T.-K., Hung, T., Chen, Y., Pan, Y., Hsieh, Y., & Tsai, J. (2023) · Environmental Toxicology · doi:10.1002/tox.23999 · Cited by 8
MAPKs’ status at early stages of renal carcinogenesis and tumors induced by ferric nitrilotriacetate
Aguilar-Alonso, F. A., Solano, J. D., Vargas-Olvera, C. Y., Pacheco-Bernal, I., Pariente-Pérez, T. O., & Ibarra‐Rubio, M. E. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2375-5 · Cited by 6
Multiregion Quantification of Extracellular Signal-regulated Kinase Activity in Renal Cell Carcinoma
Hoerner, C. R., Massoudi, R. A., Metzner, T. J., Stell, L., O'Rourke, J., Kong, C. S., Liliental, J., Brooks, J. D., Sabatti, C., Leppert, J. T., et al. (2018) · European Urology Oncology · doi:10.1016/j.euo.2018.09.011 · Cited by 3
RKIP is commonly downregulated in clear cell renal cell carcinoma (ccRCC)
(2015) · Cancer Cell & Microenvironment · doi:10.14800/ccm.445 · Cited by 1
Stem cells and cancer: A review
Ullah, N., Liaqat, S., Fatima, S., Zehra, F., Anwer, M., & Sadiq, M. (2016) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(15)61057-x · Cited by 1
Developing an algorithm for the management of Renal Cell Carcinoma: focus on metastatic disease
Kyriazoglou, A. I., Dimitriadis, I., & Bamias, A. (2017) · Forum of Clinical Oncology · doi:10.1515/fco-2015-0025 · Cited by 1
Ji, X., Yun, Y., Zhu, Z., Wu, T., Ruan, M., Fan, Y., & Zhang, Q. (2026) · Cancer Cell International · doi:10.1186/s12935-026-04266-7
“This is a crucial discovery, as constitutive activation of the ERK pathway is itself an independent factor associated with poor prognosis in RCC [36, 37].”
(2010) · Current Opinion in Urology · doi:10.1097/mou.0b013e32833dde0d
(2010) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0b013e32833a1dfc
Metadata
- Authors
- Campbell, L., Nuttall, R., Griffiths, D., & Gumbleton, M.
- Affiliations
- Cardiff University (GB)
- Corresponding author
- Gumbleton, Mark
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2009-06-12
- Volume
- 115
- Issue
- 15
- Pages
- 3457-3467
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2147716540
- Cited by
- 29
- References
- 57
- Citations by year
- 2026: 1 · 2023: 1 · 2021: 2 · 2018: 1 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- extracellular signal-regulated kinase, ERK1/2 phosphorylation, renal cell carcinoma, localized renal cell carcinoma, prognostic factors, disease-free survival, recurrence, metastasis, clear cell renal cell carcinoma, radical nephrectomy, vascular invasion, tumor grade, MAPK signaling
- MeSH terms
- Adult, Aged, Aged, 80 and over, Carcinoma, Renal Cell, Enzyme Activation, Female, Humans, Immunohistochemistry, Kidney Neoplasms, Male, Middle Aged, Prognosis, Biomarkers, Mitogen-Activated Protein Kinase 1, Tissue Array Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
